{"disease":{"id":"arthritis-psoriatic","name":"arthritis psoriatic"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT05413044","title":"A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register","phase":"","overall_status":"COMPLETED","enrollment_count":140706,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02922192","title":"Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":90360,"lead_sponsor_name":"Biologics & Biosimilars Collective Intelligence Consortium","has_results":false},{"nct_id":"NCT06568029","title":"Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease","phase":"","overall_status":"COMPLETED","enrollment_count":77651,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03456206","title":"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":57053,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT05421442","title":"A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database","phase":"","overall_status":"COMPLETED","enrollment_count":38396,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01965132","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT03496831","title":"Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Simon Krabbe","has_results":false},{"nct_id":"NCT01078558","title":"A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )","phase":"","overall_status":"COMPLETED","enrollment_count":5940,"lead_sponsor_name":"AbbVie (prior sponsor, Abbott)","has_results":true},{"nct_id":"NCT04190758","title":"GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5100,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT03470688","title":"Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Opal Rheumatology Ltd.","has_results":false},{"nct_id":"NCT04655612","title":"Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT06714461","title":"A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04821206","title":"PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Liga Panamericana de Asociaciones de Reumatologia (PANLAR)","has_results":false},{"nct_id":"NCT00741793","title":"Biologic Treatment Registry Across Canada","phase":"","overall_status":"COMPLETED","enrollment_count":2821,"lead_sponsor_name":"Janssen Inc.","has_results":false},{"nct_id":"NCT05883371","title":"IMPACT - AndHealth Autoimmune Research Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"AndHealth","has_results":false},{"nct_id":"NCT04541810","title":"A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2369,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04798625","title":"Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT03662919","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2274,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05039216","title":"Biobank for Inflammatory Chronic Diseases and Osteoporosis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT07223138","title":"A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1560,"lead_sponsor_name":"MoonLake Immunotherapeutics AG","has_results":false},{"nct_id":"NCT02486302","title":"A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.","phase":"","overall_status":"COMPLETED","enrollment_count":1534,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02925338","title":"National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life","phase":"","overall_status":"COMPLETED","enrollment_count":1431,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05049798","title":"A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Janssen Pharmaceutica N.V., Belgium","has_results":false},{"nct_id":"NCT01081717","title":"Golimumab Safety and Surveillance Program Using the Ingenix NHI Database","phase":"","overall_status":"COMPLETED","enrollment_count":1064,"lead_sponsor_name":"Janssen Biotech, Inc.","has_results":false},{"nct_id":"NCT04882098","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1054,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT05190484","title":"bIosimilar of aDalimumab, an European evAluation","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT02984020","title":"Korean Post-marketing Surveillance for Xeljanz","phase":"","overall_status":"COMPLETED","enrollment_count":1041,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT05621369","title":"Psorcast Mobile Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sage Bionetworks","has_results":false},{"nct_id":"NCT04089514","title":"A Real-world Study of Imraldi® Use","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06059430","title":"Cohort Project of Patients With Inflammatory Rheumatism","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06641076","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":960,"lead_sponsor_name":"MoonLake Immunotherapeutics AG","has_results":false},{"nct_id":"NCT05080218","title":"COVID-19 VaccinE Response in Rheumatology Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":841,"lead_sponsor_name":"Jeffrey Curtis","has_results":false},{"nct_id":"NCT04347798","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","phase":"","overall_status":"COMPLETED","enrollment_count":773,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT05677542","title":"Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study","phase":"","overall_status":"COMPLETED","enrollment_count":758,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05051943","title":"A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response","phase":"","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT06807424","title":"A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03158285","title":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":741,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT01976364","title":"Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":686,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05458531","title":"Monitoring of Inflammatory Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":664,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03074656","title":"The Norwegian Drug Monitoring Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT05598684","title":"SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Fresenius Kabi, France","has_results":false},{"nct_id":"NCT06641089","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"MoonLake Immunotherapeutics AG","has_results":false},{"nct_id":"NCT04582084","title":"Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":583,"lead_sponsor_name":"AryoGen Pharmed Co.","has_results":false},{"nct_id":"NCT04345159","title":"Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT06878404","title":"A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":552,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}